이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

만성 샤가스병 환자에서 LXE408의 효능, 안전성, 내약성에 관한 연구.

2026년 11월 9일 업데이트: Novartis Pharmaceuticals

심각한 기관 기능 장애가 없는 만성 샤가스병 참가자에서 LXE408의 효능, 안전성, 내약성, 약동학 및 약력학을 평가하기 위한 무작위, 참가자 및 조사자 맹검, 대조, 병렬 그룹 연구.

This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.

연구 개요

상세 설명

This is an interventional, phase 2, PoC (Proof of Concept) randomized, participant- and investigator-blinded, controlled, parallel group study, with 4 treatment arms. The purpose of this study is to assess the efficacy (anti-parasitological activity), safety, PK (pharmacokinetics), and PD (pharmacodynamics) of LXE408 in participants with CICD (chronic indeterminate Chagas disease) and chronic Chagas disease without severe cardiac or gastrointestinal dysfunction compared to placebo and to benznidazole.

연구 유형

중재적

등록 (추정된)

130

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Novartis Pharmaceuticals
  • 전화번호: +41613241111

연구 장소

    • California
      • Sylmar, California, 미국, 91342
        • 모병
        • Olive View UCLA Educ and Res Ins
        • 수석 연구원:
          • Jonathan Soverow
        • 연락하다:
    • Florida
      • Gainesville, Florida, 미국, 32610-0486
        • 모병
        • University of Florida Shands
        • 수석 연구원:
          • Norman Beatty
        • 연락하다:
    • Massachusetts
      • Boston, Massachusetts, 미국, 02118
        • 모병
        • Boston Medical Center
        • 수석 연구원:
          • Dan Bourque
        • 연락하다:
    • Texas
      • Houston, Texas, 미국, 77030-3411
        • 모병
        • Baylor College of Medicine
        • 수석 연구원:
          • Eva Clark
        • 연락하다:
    • Minas Gerais
      • Montes Claros, Minas Gerais, 브라질, 39401-001
        • 모병
        • Novartis Investigative Site
    • Pernambuco
      • Recife, Pernambuco, 브라질, 50100-060
        • 모병
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, 브라질, 90601-000
        • 모병
        • Novartis Investigative Site
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, 브라질, 21040-360
        • 모병
        • Novartis Investigative Site
    • São Paulo
      • São Caetano do Sul, São Paulo, 브라질, 09521-160
        • 모병
        • Novartis Investigative Site
      • São Paulo, São Paulo, 브라질, 01232-010
        • 모병
        • Novartis Investigative Site
      • Caba, 아르헨티나, C1015ABO
        • 모병
        • Novartis Investigative Site
      • Corrientes, 아르헨티나, W3400CDS
        • 모병
        • Novartis Investigative Site
      • Formosa, 아르헨티나, P3600KGC
        • 모병
        • Novartis Investigative Site
    • Buenos Aires
      • CABA, Buenos Aires, 아르헨티나, C1221ADC
        • 모병
        • Novartis Investigative Site
      • CABA, Buenos Aires, 아르헨티나, C1407FWE
        • 모병
        • Novartis Investigative Site
    • Córdoba Province
      • Córdoba, Córdoba Province, 아르헨티나, X5016KEH
        • 모병
        • Novartis Investigative Site
      • Bogotá, 콜롬비아, 110131
        • 모병
        • Novartis Investigative Site
      • Bogotá, 콜롬비아, 111411
        • 모병
        • Novartis Investigative Site
      • Floridablanca, 콜롬비아, 681017
        • 모병
        • Novartis Investigative Site
      • San Gil, 콜롬비아, 684031
        • 모병
        • Novartis Investigative Site
    • Atlántico
      • Barranquilla, Atlántico, 콜롬비아, 080005
        • 모병
        • Novartis Investigative Site
    • Casanare Department
      • Yopal, Casanare Department, 콜롬비아, 850009
        • 모집하지 않고 적극적으로
        • Novartis Investigative Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Male or female participants aged ≥ 18 years to ≤ 60 years old
  • Confirmed diagnosis of T. cruzi infection
  • History that participant has been determined to be in chronic phase of CD
  • Written informed consent must be obtained before any assessment is performed, and participants should express understanding of the consent form and the study
  • Participants must be considered by the investigator eligible for and able to comply with local prescribing information for benznidazole
  • Ability and willingness to communicate well with the investigator/study site and comply with requirements of the study

Exclusion Criteria:

  • Signs (on physical examination) and/or symptoms of CD in the acute phase as determined by the investigator at screening

  • History of CD treatment with benznidazole or nifurtimox at any time in the past

  • History of and/or current (at screening) symptoms or signs (physical examination findings) of moderate or severe CD-related gastrointestinal disease

  • Participants who weigh < 50 kg or >90kg at screening

  • At sites conducting the MRI assessments, participants may participate in the overall study, but will be excluded from the MRI assessment if they have contraindications to MRI imaging

  • Any clinically significant disease during screening that, in the opinion of the investigator, would put the safety of the participant at risk through participating, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study, or would compromise participant compliance or preclude completion of the study

  • Documented history or current findings at screening of clinically significant cardiovascular conditions such as, but not limited to: unstable ischemic heart disease; NYHA Class III/IV heart failure (due to Chagas disease or other conditions); arrhythmias

  • Known or suspected ongoing, chronic or recurrent viral, bacterial or fungal infectious diseases including but not limited to: Tuberculosis, leishmaniasis, severe malaria, atypical mycobacterial infection, listeriosis, aspergillosis, or endemic mycoses, and/or documented positivity for human immunodeficiency virus (HIV) infection.

    • Participants with controlled HIV on antiretroviral therapy are eligible to participate if CD4 ≥ 500 at screening
  • History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years prior to screening (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed)

  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant during the study period

    • Pancreatic injury or pancreatitis: If any single parameter of amylase or lipase exceeds 1.5x ULN at screening Participants with known recurrent pancreatitis (more than 1 episode in lifetime, from any cause) are excluded
    • Liver disease or liver injury as indicated by abnormal liver function tests (LFTs):

Any single parameter of ALT, AST, alkaline phosphatase must not exceed 1.5x ULN at screening Serum bilirubin must not exceed the ULN at screening elevated serum bilirubin is not excluded if there is a documented history of Gilbert's Syndrome

  • History of renal disease as indicated by creatinine level above 1.5x ULN or microalbuminuria at screening; Evidence of urinary obstruction, or difficulty in voiding at screening; evidence of congenital renal abnormalities with known effect on renal function; calculated eGFR <60 mL/min (<0.835 mL/s) using the CKD-EPI formula for adults

    • Participants with screening hematology parameters outside of the thresholds
    • Current use of medications prohibited by the protocol at screening and/or baseline visits, or expected use of any prohibited medication during the study treatment period
  • Use of benznidazole in the blinded arms is prohibited until unblinding occurs after all participants complete Month 12.

    • Use of other investigational drugs at the time of study drug dosing
    • History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study or to benznidazole
    • History of drug abuse or unhealthy alcohol use within the 12 months prior to dosing
    • Pregnant or nursing (lactating/breast-feeding) women
    • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 5 days after stopping of investigational drug and benznidazole
    • Participants who, in the opinion of the investigator, will not be able to comply with study procedures or visits, adhere to dosing schedule, or other otherwise be in compliance with study requirements

Other protocol-defined inclusion/exclusion criteria may apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: LXE408 28 days

LXE408 administered by oral route

실험적: LXE408 14 days and Placebo 14 days

LXE408 administered by oral route, followed by Placebo administered by oral route

LXE408 administered by oral route

Placebo administered by oral route

위약 비교기: Placebo 28 days

Placebo administered by oral route

Placebo administered by oral route

활성 비교기: Benznidazole 60 days

Benznidazole administered by oral route

Benznidazole administered by oral route (administered as standard of care)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 28 days versus placebo.
기간: At Months 2, 4, and 6

The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.

At Months 2, 4, and 6

2차 결과 측정

결과 측정
측정값 설명
기간
Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 -14 days versus placebo
기간: At Months 2, 4, and 6

The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.

At Months 2, 4, and 6
Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months-LXE408 - 28 days and 14 days versus benznidazone
기간: At Months 2, 4, and 6

The parasitological load will be measured using polymerase chain reaction (PCR) at 2 months, 4 months, and at 6 months. At each timepoint, multiple samples are evaluated. The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all 3 visits.

At Months 2, 4, and 6
Presence or absence of early parasitological clearance
기간: At Day 7, 14 and 28

The parasitological load will be measured using polymerase chain reaction (PCR). The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample.

At Day 7, 14 and 28
Presence or absence of sustained parasitological clearance over 12 months by PCR testing
기간: 12 Months

The parasitological load will be measured using polymerase chain reaction (PCR). The participant will be considered negative at a visit if the parasite is not detectable in all samples at a visit and positive if the parasite level is detectable in at least one sample. Sustained parasitological clearance is achieved if participant is negative at all subsequent visits.

12 Months
Time to parasitological clearance based on serial PCR testing
기간: 12 Months

Time to parasitological clearance based on PCR by treatment will be estimated using the Kaplan-Meier approach.

12 Months
Presence or absence of seroreversion using conventional serology
기간: At Month 6 and Month 12

Seroreversion as measured by conventional serology will be evaluated at 6 and 12-month study visits. Seroreversion is determined by the proportion of participants achieving serology changes from positive at baseline to negative at each time point.

At Month 6 and Month 12
Occurrence and severity of treatment emergent adverse events during the study
기간: Up to 12 Months

Incidence and severity of AEs by treatment group, including changes in the vital signs, electrocardiogram and laboratory results qualifying and reported as AEs.

Up to 12 Months
Occurrence of adverse events resulting in treatment discontinuation
기간: Up to 12 Months

Incidence of AEs that result in treatment discontinuation.

Up to 12 Months
Occurrence of all-cause mortality through end of study visit
기간: Up to 48 Months

Incidence of death through the end of study visit.

Up to 48 Months
Maximum plasma concentration (Cmax) of LXE408
기간: At Day 1, 7, 14, 28

Cmax is defined as the maximum (peak) observed concentration following a dose.

At Day 1, 7, 14, 28
Time to maximum plasma concentration (Tmax) of LXE408
기간: At Day 1, 7, 14, 28

Tmax is defined as the time to reach maximum (peak) concentration following a dose.

At Day 1, 7, 14, 28
Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8)
기간: At Day 1, 7, 14, 28

AUC0-8 will be calculated by non-compartmental methods based on LXE408 plasma concentration data.

At Day 1, 7, 14, 28
Pre-dose concentration
기간: At Day 14 and Day 28

Pre-dose concentration is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.

At Day 14 and Day 28

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 28일

기본 완료 (추정된)

2027년 7월 22일

연구 완료 (추정된)

2031년 1월 21일

연구 등록 날짜

최초 제출

2024년 10월 7일

QC 기준을 충족하는 최초 제출

2024년 10월 7일

처음 게시됨 (실제)

2024년 10월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다